

# Ir-catalyzed asymmetric allylic alkylation using chiral diaminophosphine oxides: DIAPHOXs. Formal enantioselective synthesis of (–)-paroxetine

Tetsuhiro Nemoto, Tatsuro Sakamoto, Takashi Fukuyama and Yasumasa Hamada\*

Graduate School of Pharmaceutical Sciences, Chiba University, Yayoi-cho, Inage-ku, Chiba 263-8522, Japan


Received 24 April 2007; revised 18 May 2007; accepted 22 May 2007

Available online 24 May 2007

**Abstract**—An Ir-catalyzed asymmetric allylic alkylation using chiral diaminophosphine oxide is described. Asymmetric allylic alkylation of terminal allylic carbonates proceeded using 5 mol % of Ir catalyst, 5 mol % of DIAPHOX **1i**, 10 mol % of NaPF<sub>6</sub>, 10 mol % of LiOAc, and *N,O*-bis(trimethylsilyl)acetamide (BSA), affording the corresponding branched products in excellent yield and in up to 95% ee. The developed catalytic asymmetric reaction was successfully applied to a formal enantioselective synthesis of (–)-paroxetine.

© 2007 Elsevier Ltd. All rights reserved.

Transition-metal catalyzed asymmetric allylic alkylation is one of the most powerful methods for introducing chirality on the allylic carbon. Various types of asymmetric allylic alkylations have been reported.<sup>1</sup> Pd-catalyzed asymmetric allylic alkylation normally favors nucleophilic addition to the less substituted allylic terminus, although ligands can influence this selectivity.<sup>2</sup> In contrast, asymmetric allylic alkylation using W-,<sup>3</sup> Mo-,<sup>4</sup> Ir-,<sup>5</sup> and Rh-catalysts<sup>6</sup> favors attack at the more substituted terminus, providing chiral branched products regioselectively.<sup>7</sup> We recently reported that aspartic acid-derived P-chirogenic diaminophosphine oxides (DIAPHOXs) are useful chiral preligands in several Pd-catalyzed asymmetric allylic substitutions.<sup>8,9</sup> In these reactions, chiral diaminophosphine oxides are activated in situ by *N,O*-bis(trimethylsilyl)acetamide (BSA)-induced tautomerization, affording trivalent diamidophosphite species, which function as the actual ligands (Scheme 1). The present chiral ligand system was also applicable to Ir-catalyzed asymmetric allylic amination of terminal allylic carbonates to give branched allylic amines, which was dramatically accelerated by the addition of NaPF<sub>6</sub>.<sup>10</sup> The success of the asymmetric allylic amination led us to examine asym-




Scheme 1. BSA-induced tautomerization of DIAPHOXs.

metric allylic alkylation using the Ir–DIAPHOX–NaPF<sub>6</sub> catalyst system.<sup>11,12</sup> We report herein an Ir-catalyzed asymmetric allylic alkylation using DIAPHOXs. The developed catalytic asymmetric reaction was successfully applied to the formal enantioselective synthesis of (–)-paroxetine.


We first examined asymmetric allylic alkylation of cinnamyl carbonate **2a** with dimethyl malonate using (*S,R*<sub>p</sub>)-**1a** (Table 1 and Fig. 1). Although no reaction occurred when 2.5 mol % of chloro(1,5-cyclooctadiene)iridium(I) dimer ([Ir(cod)Cl]<sub>2</sub>) and 5 mol % of (*S,R*<sub>p</sub>)-**1a** (Ir/**1a** = 1/1) were used, the same reaction proceeded in the presence of 10 mol % of NaPF<sub>6</sub>, affording branched product (*S*)-**3a** with high regioselectivity (29% yield, **3a/3a'** = 97/3, 75% ee) (entry 1).<sup>13</sup> The addition of LiCl remarkably increases both reactivity and enantioselectivity in the Ir-catalyzed asymmetric allylic alkylation.<sup>5b,c,g</sup> Thus, we investigated the effect of

**Keywords:** Asymmetric allylic alkylation; Asymmetric catalysis; Diaminophosphine oxide; Iridium; Paroxetine.

\* Corresponding author. Tel./fax: +81 43 290 2987; e-mail: hamada@p.chiba-u.ac.jp

**Table 1.** Optimization of the reaction conditions


Entry	Additive	Conc. (M)	Time (h)	Yield <sup>a</sup> (%)	Ratio <sup>b</sup> ( <b>3a/3a'</b> )	ee <sup>c</sup> (% ee)
1	—	0.4	24	29	97/3	75
2	LiCl	0.4	24	95	97/3	72
3	LiOAc	0.4	24	71	95/5	90
4	NaOAc	0.4	24	39	93/7	73
5	KOAc	0.4	24	36	95/5	80
6	CsOAc	0.4	24	38	97/3	85
7	Mg(OAc) <sub>2</sub> ·4H <sub>2</sub> O	0.4	24	77	99/1	80
8	Zn(OAc) <sub>2</sub>	0.4	24	93	98/2	60
9	In(OAc) <sub>3</sub>	0.4	24	92	98/2	60
10	Bu <sub>4</sub> NOAc	0.4	24	42	99/1	60
11	LiOAc	0.5	24	73	96/4	88
12	LiOAc	0.25	24	90	95/5	88

<sup>a</sup> Isolated yield of **3a**+**3a'**.<sup>b</sup> Determined by <sup>1</sup>H NMR analysis of the crude sample.<sup>c</sup> Determined by HPLC analysis.**Figure 1.** (*S,Rp*)-DIAPHOXs.

additives in detail. Although reactivity was significantly improved when LiCl was used as the additive, there was a slight decrease in the enantioselectivity (entry 2). Both reactivity and enantioselectivity, on the other hand, were affected by the addition of acetate salts (entries 3–10). The best enantioselectivity (90% ee) was obtained when LiOAc was used as the additive (entry 3). Further optimization with regard to the reaction concentration resulted in the formation of branched product (*S*)-**3a** in good yield (90% yield, **3a/3a'** = 95/5) with 88% ee. The increased reactivity under the diluted reaction condition is likely related to the solubility of LiOAc in CH<sub>2</sub>Cl<sub>2</sub> (entries 3, 11, and 12). We next attempted to improve the regioselectivity and enantioselectivity by tuning the structure of DIAPHOX (Table 2). Studies of the effect of substituents on the aromatic rings revealed that DIAPHOX **1i**, which possesses a 3-biphenyl group at the benzylic moiety, was best for asymmetric induction (90% ee), giving the branched product (*S*)-**3a** in good yield with excellent regioselectivity (93% yield, **3a/3a'** = 99/1) (entry 9).

Having developed efficient conditions,<sup>14</sup> we examined the scope and limitations of different substrates (Table 3). Using 5 mol % of Ir catalyst, 5 mol % of (*S,Rp*)-**1i**, 10 mol % of NaPF<sub>6</sub>, and 10 mol % of LiOAc, asymmet-

**Table 2.** Ir-catalyzed asymmetric allylic substitution of **2a** with dimethyl malonate using **1a–i**<sup>a</sup>

Entry	DIAPHOX	Time (h)	Yield <sup>b</sup> (%)	Ratio <sup>c</sup> ( <b>3a/3a'</b> )	ee <sup>d</sup> (% ee)
1	<b>1a</b>	24	90	95/5	88
2	<b>1b</b>	24	94	98/2	88
3	<b>1c</b>	24	98	96/4	85
4	<b>1d</b>	24	78	90/10	45
5	<b>1e</b>	24	17	97/3	85
6	<b>1f</b>	24	54	95/5	57
7	<b>1g</b>	24	69	96/4	74
8	<b>1h</b>	24	92	97/3	82
9	<b>1i</b>	24	92	99/1	90

<sup>a</sup> Conditions: Ir cat. (5 mol %), (*S,Rp*)-DIAPHOX (5 mol %), NaPF<sub>6</sub> (10 mol %), LiOAc (10 mol %), dimethyl malonate (3 equiv), BSA (3 equiv), CH<sub>2</sub>Cl<sub>2</sub> (0.25 M).<sup>b</sup> Isolated yield of **3a**+**3a'**.<sup>c</sup> Determined by <sup>1</sup>H NMR analysis of the crude sample.<sup>d</sup> Determined by HPLC analysis.

ric allylic alkylation of various terminal allylic carbonates were performed using dimethyl malonate as the nucleophile. Terminal allylic carbonates with an electron-donating group, as well as an electron-withdrawing group, on the aromatic ring are tolerated in this reaction, giving the corresponding branched products in good yield with high regio- and enantioselectivity (entries 1–8). In addition, terminal allylic carbonates with a naphthyl substituent (entries 9 and 10) or a heteroaromatic substituent (entry 11) were also applicable to this reaction, affording the corresponding product with good enantioselectivity. On the other hand, asymmetric allylic alkylation of **2l**, a substrate with an alkyl substituent, gave the linear product predominantly (branched/linear = 39/61) and the enantiomeric excess of the branched product was moderate (entry 12).

Thus, the present catalytic asymmetric reaction had broad generality for  $\gamma$ -aryl substituted-terminal allylic

Table 3. Substrate scope

Entry	Substrate	Product	Time (h)	Yield <sup>a</sup> (%)	Ratio <sup>b</sup> (3/3')	ee <sup>c</sup> (% ee)
1	<b>2a</b> : R = C <sub>6</sub> H <sub>5</sub>	<b>3a</b>	24	93	99/1	90 ( <i>S</i> )
2	<b>2b</b> : R = 4-MeO-C <sub>6</sub> H <sub>4</sub>	<b>3b</b>	48	93	99/1	93
3	<b>2c</b> : R = 4-Cl-C <sub>6</sub> H <sub>4</sub>	<b>3c</b>	48	99	95/5	95
4	<b>2d</b> : R = 4-F-C <sub>6</sub> H <sub>4</sub>	<b>3d</b>	36	93	99/1	92 ( <i>S</i> )
5	<b>2e</b> : R = 3-MeO-C <sub>6</sub> H <sub>4</sub>	<b>3e</b>	72	99	97/3	90
6	<b>2f</b> : R = 3-F-C <sub>6</sub> H <sub>4</sub>	<b>3f</b>	36	93	95/5	89
7	<b>2g</b> : R = 2-MeO-C <sub>6</sub> H <sub>4</sub>	<b>3g</b>	48	91	97/3	87
8	<b>2h</b> : R = 2-F-C <sub>6</sub> H <sub>4</sub>	<b>3h</b>	36	92	97/3	92
9	<b>2i</b> : R = 1-Naphthyl	<b>3i</b>	36	99	99/1	90
10	<b>2j</b> : R = 2-Naphthyl	<b>3j</b>	36	99	97/3	91
11	<b>2k</b> : R = 2-Furyl	<b>3k</b>	36	91	99/1	88
12	<b>2l</b> : R = C <sub>6</sub> H <sub>5</sub> CH <sub>2</sub> CH <sub>2</sub>	<b>3l</b>	36	95	39/61	60

<sup>a</sup> Isolated yield of the branched and linear products.


<sup>b</sup> Determined by <sup>1</sup>H NMR analysis of the crude sample.

<sup>c</sup> Determined by HPLC analysis.

carbonates, affording the corresponding branched products in excellent yield with high regio- and enantioselectivity. To demonstrate the synthetic utility, we applied the developed reaction system to the formal enantioselective synthesis of (–)-paroxetine **4**.

(–)-Paroxetine hydrochloride, marketed as Paxil/Seroxat, is a selective serotonin reuptake inhibitor used in the treatment of depression, obsessive-compulsive disorder, and panic disorder.<sup>15</sup> As one of the leading prescription drugs worldwide, (–)-paroxetine has received considerable attention from synthetic chemists. Therefore, there have been several studies on the catalytic asymmetric synthesis of (–)-paroxetine.<sup>16,17</sup> A formal enantioselective synthesis of (–)-paroxetine using Ir-catalyzed asymmetric allylic alkylation is outlined in Scheme 2. First, Ir-catalyzed asymmetric allylic alkylation of **2d** with dimethyl malonate was performed using (*R,S*)-**1i**, affording (*R*)-**3d** in 90% yield (branched/linear = 99/1) with 92% ee. Hydroboration of the olefin with 9-BBN in the presence of Wilkinson's catalyst, followed by work-up with hydrogen peroxide gave **5** in 85% yield.<sup>18</sup> After conversion of the hydroxyl group to an azide group (90% yield), **6** was treated with Lindlar's catalyst in toluene/MeOH (5/1) under hydrogen atmosphere to provide lactam **7** in 93% yield as a single diastereomer (*anti/syn* >99/1). Subsequent reduction of **7** with BH<sub>3</sub>·THF complex gave (3*S*,4*R*)-(–)-**8** in 99% yield ([α]<sub>D</sub><sup>23</sup> –17.0 (*c* 0.90, MeOH, 92% ee),<sup>19</sup> literature data: [α]<sub>D</sub><sup>23</sup> –21.7 (*c* 0.41, MeOH), (3*S*,4*R*)-isomer).<sup>17e</sup> The known intermediate **8** can be converted into **4** using the reported procedure.<sup>16c</sup>

In conclusion, we achieved the Ir-catalyzed asymmetric allylic alkylation using chiral diaminophosphine oxides: DIAPHOXs. Using the developed catalyst system, branched products were obtained in excellent yield with high regio- and enantioselectivity. In addition, the developed catalytic asymmetric reaction was success-



Scheme 2. Formal enantioselective synthesis of (–)-paroxetine.

fully applied to the formal enantioselective synthesis of (–)-paroxetine. Mechanistic investigations into the role of additives, as well as the structure of the catalytically active species, are currently in progress.

#### Acknowledgement

This work was supported in part by Grant-in-Aid for Encouragement of Young Scientists (A) from the

Ministry of Education, Culture, Sports, Science, and Technology, Japan.

### Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.tetlet.2007.05.120.

### References and notes

- For reviews on transition-metal catalyzed asymmetric allylic substitution reactions, see: (a) Trost, B. M.; Van Vranken, D. L. *Chem. Rev.* **1996**, *96*, 395–422; (b) Trost, B. M.; Crawley, M. L. *Chem. Rev.* **2003**, *103*, 2921–2943.
- For representative examples, see: (a) Hayashi, T.; Kawatsura, M.; Uozumi, Y. *J. Chem. Soc., Chem. Commun.* **1997**, 561–562; (b) Prétôt, R.; Pfaltz, A. *Angew. Chem., Int. Ed.* **1998**, *37*, 323–325; (c) You, S.-L.; Zhu, X.-Z.; Luo, Y.-M.; Hou, X.-L.; Dai, L.-X. *J. Am. Chem. Soc.* **2001**, *123*, 7471–7472; (d) Pàmies, O.; Diéguez, M.; Claver, C. *J. Am. Chem. Soc.* **2005**, *127*, 3646–3647; (e) Zheng, W. H.; Sun, N.; Hou, X. L. *Org. Lett.* **2005**, *7*, 5151–5154.
- Lloyd-Jones, G. C.; Pfaltz, A. *Angew. Chem., Int. Ed. Engl.* **1995**, *34*, 462–464.
- (a) Trost, B. M.; Hachiya, I. *J. Am. Chem. Soc.* **1998**, *120*, 1104–1105; (b) Trost, B. M.; Hildbrand, S.; Dogra, K. *J. Am. Chem. Soc.* **1999**, *121*, 10416–10417; (c) Trost, B. M.; Dogra, K. *J. Am. Chem. Soc.* **2002**, *124*, 7256–7257; (d) Trost, B. M.; Dogra, K.; Franzini, M. *J. Am. Chem. Soc.* **2004**, *126*, 1944–1945.
- (a) Janssen, J. P.; Helmchen, G. *Tetrahedron Lett.* **1997**, *38*, 8025–8026; (b) Bartels, A.; Helmchen, G. *Chem. Commun.* **1999**, 741–742; (c) Fuji, K.; Kinoshita, N.; Tanaka, K.; Kawabata, T. *Chem. Commun.* **1999**, 2289–2290; (d) Kanayama, T.; Yoshida, K.; Miyabe, H.; Takemoto, Y. *Angew. Chem., Int. Ed.* **2003**, *42*, 2054–2056; (e) Kanayama, T.; Yoshida, K.; Miyabe, H.; Kimachi, T.; Takemoto, Y. *J. Org. Chem.* **2003**, *68*, 6197–6201; (f) Kinoshita, N.; Marx, K. H.; Tanaka, K.; Tsubaki, K.; Kawabata, T.; Yoshikai, N.; Nakamura, E.; Fuji, K. *J. Org. Chem.* **2004**, *69*, 7960–7964; (g) Alexakis, A.; Polet, D. *Org. Lett.* **2004**, *6*, 3529–3532; (h) Lipowsky, G.; Miller, N.; Helmchen, G. *Angew. Chem., Int. Ed.* **2004**, *43*, 4595–4597; (i) Streiff, S.; Welter, C.; Schelwies, M.; Lipowsky, G.; Miller, N.; Helmchen, G. *Chem. Commun.* **2005**, 2957–2959; (j) Graening, T.; Hartwig, J. F. *J. Am. Chem. Soc.* **2005**, *127*, 17192–17193; (k) Polet, D.; Alexakis, A.; Tissot-Croset, K.; Corminboeuf, C.; Ditrach, K. *Chem. Eur. J.* **2006**, *12*, 3596–3609.
- Hayashi, T.; Okada, A.; Suzuka, T.; Kawatsura, M. *Org. Lett.* **2003**, *5*, 1713–1715.
- For enantiospecific allylic alkylation using transition metal catalysts, see Ru catalyst: (a) Trost, B. M.; Fraise, P. L.; Ball, Z. T. *Angew. Chem., Int. Ed.* **2002**, *41*, 1059–1061; Rh catalyst: (b) Evans, P. A.; Nelson, J. D. *J. Am. Chem. Soc.* **1998**, *120*, 5581–5582; (c) Evans, P. A.; Leahy, D. K. *J. Am. Chem. Soc.* **2003**, *125*, 8974–8975; (d) Evans, P. A.; Lawler, M. J. *J. Am. Chem. Soc.* **2004**, *126*, 8642–8643.
- (a) Nemoto, T.; Matsumoto, T.; Masuda, T.; Hitomi, T.; Hatano, K.; Hamada, Y. *J. Am. Chem. Soc.* **2004**, *126*, 3690–3691; (b) Nemoto, T.; Masuda, T.; Matsumoto, T.; Hamada, Y. *J. Org. Chem.* **2005**, *70*, 7172–7178; (c) Nemoto, T.; Fukuda, T.; Matsumoto, T.; Hitomi, T.; Hamada, Y. *Adv. Synth. Catal.* **2005**, *347*, 1504–1506; (d) Nemoto, T.; Masuda, T.; Akimoto, Y.; Fukuyama, T.; Hamada, Y. *Org. Lett.* **2005**, *7*, 4447–4450; (e) Nemoto, T.; Jin, L.; Nakamura, H.; Hamada, Y. *Tetrahedron Lett.* **2006**, *47*, 6577–6581; (f) Nemoto, T.; Fukuyama, T.; Yamamoto, E.; Tamura, S.; Fukuda, T.; Matsumoto, T.; Akimoto, Y.; Hamada, Y. *Org. Lett.* **2007**, *9*, 927–930.
- For reviews on transition metal catalysis using phosphine oxide preligands, see: (a) Dubrovina, N. V.; Börner, A. *Angew. Chem., Int. Ed.* **2004**, *43*, 5883–5886; (b) Ackermann, L. *Synthesis* **2006**, 1557–1571; (c) Ackermann, L. *Synlett* **2007**, 507–526.
- Nemoto, T.; Sakamoto, T.; Matsumoto, T.; Hamada, Y. *Tetrahedron Lett.* **2006**, *47*, 8737–8740.
- (a) Takeuchi, R.; Kashio, M. *Angew. Chem., Int. Ed.* **1997**, *36*, 263–265; (b) Takeuchi, R.; Kashio, M. *J. Am. Chem. Soc.* **1998**, *120*, 8647–8655; (c) Takeuchi, R.; Ue, N.; Tanabe, K.; Yamashita, K.; Shiga, N. *J. Am. Chem. Soc.* **2001**, *123*, 9525–9534; (d) Takeuchi, R. *Synlett* **2002**, 1954–1965.
- For other representative examples of Ir-catalyzed asymmetric allylic substitution using nitrogen or oxygen nucleophiles, see: (a) Ohmura, T.; Hartwig, J. F. *J. Am. Chem. Soc.* **2002**, *124*, 15164–15165; (b) Kiener, C. A.; Shu, C.; Incarvito, C.; Hartwig, J. F. *J. Am. Chem. Soc.* **2003**, *125*, 14272–14273; (c) Shu, C.; Hartwig, J. F. *Angew. Chem., Int. Ed.* **2004**, *43*, 4794–4797; (d) Shu, C.; Leiner, A.; Hartwig, J. F. *Angew. Chem., Int. Ed.* **2004**, *43*, 4797–4800; (e) Tissot-Croset, K.; Polet, D.; Alexakis, A. *Angew. Chem., Int. Ed.* **2004**, *43*, 2426–2428; (f) Lipowsky, G.; Helmchen, G. *Chem. Commun.* **2004**, 896–897; (g) Miyabe, H.; Matsumura, A.; Moriyama, K.; Takemoto, Y. *Org. Lett.* **2004**, *6*, 4631–4634; (h) Leitner, A.; Shekhar, S.; Pouy, M. J.; Hartwig, J. F. *J. Am. Chem. Soc.* **2005**, *127*, 15506–15514; (i) Weihofen, R.; Tverskoy, O.; Helmchen, G. *Angew. Chem., Int. Ed.* **2006**, *45*, 5546–5549; (j) Lyothier, I.; Defieber, C.; Carreira, E. M. *Angew. Chem., Int. Ed.* **2006**, *45*, 6204–6207; (k) Kimura, M.; Uozumi, Y. *J. Org. Chem.* **2007**, *72*, 707–714; For a review, see: (l) Helmchen, G.; Dahnz, A.; Dübon, P.; Schelwies, M.; Weihofen, R. *Chem. Commun.* **2007**, 675–691.
- Asymmetric allylic alkylation of **2a** with dimethyl malonate in the presence of other hexafluorophosphate salts gave less satisfactory results. NaPF<sub>6</sub>: 24 h, 29%, **3a/3a'** = 97/3, 75% ee (Table 1, entry 1), LiPF<sub>6</sub>: 24 h, 76%, **3a/3a'** = 82/18, 81% ee, KPF<sub>6</sub>: 24 h, 6%, **3a/3a'** = 97/3, 23% ee, AgPF<sub>6</sub>: 24 h, 42%, **3a/3a'** = 97/3, 45% ee. These results indicate that the counter cation of hexafluorophosphate salt might also play an important role in the present asymmetric catalysis.
- General procedure for the Ir-catalyzed asymmetric allylic alkylation (Table 3, entry 1): To a stirred mixture of [Ir(cod)Cl]<sub>2</sub> (3.46 mg, 0.00515 mmol), (*S,R*)-**1i** (4.82 mg, 0.0103 mmol), NaPF<sub>6</sub> (3.46 mg, 0.0206 mmol), LiOAc (1.40 mg, 0.0206 mmol), and **2a** (39.6 mg, 0.206 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (0.82 mL) at room temperature was added BSA (147 μL, 0.618 mmol), and the solution was stirred for 5 min at the same temperature. Dimethyl malonate (70 μL, 0.618 mmol) was added and the resulting mixture was stirred for 24 h. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by flash column chromatography (SiO<sub>2</sub>, hexane/ethyl acetate: 20/1) to give (*S*)-**3a** as colorless oil (47.5 mg, 93%, 90% ee, **3a/3a'** = 99/1).
- For a review, see: Gunasekara, N. G.; Noble, S.; Benfield, P. *Drugs* **1998**, *55*, 85–120.
- (a) Senda, T.; Ogasawara, M.; Hayashi, T. *J. Org. Chem.* **2001**, *66*, 6852–6856; (b) Taylor, M. S.; Jacobsen, E. N. *J. Am. Chem. Soc.* **2003**, *125*, 11204–11205; (c) Hughes, G.;

- Kimura, M.; Buchwald, S. L. *J. Am. Chem. Soc.* **2003**, *125*, 11253–11258; (d) Brandau, S.; Landa, A.; Franzén, J.; Marigo, M.; Jørgensen, K. A. *Angew. Chem., Int. Ed.* **2006**, *45*, 4305–4309; (e) Koech, P. K.; Krische, M. J. *Tetrahedron* **2006**, *62*, 10594–10602; (f) Ito, M.; Sakaguchi, A.; Kobayashi, C.; Ikariya, T. *J. Am. Chem. Soc.* **2007**, *129*, 290–291; (g) Bower, J. F.; Riis-Johannessen, T.; Szeto, P.; Whitehead, A. J.; Gallagher, T. *Chem. Commun.* **2007**, 728–730.
17. For examples of asymmetric syntheses of paroxetine, see: (a) Yu, M. S.; Lantos, I.; Peng, Z.-Q.; Yu, J.; Cacchio, T. *Tetrahedron Lett.* **2000**, *41*, 5647–5651; (b) Amat, M.; Bosch, J.; Hidalgo, J.; Canto, M.; Perez, M.; Llor, N.; Molins, E.; Miravittles, C.; Orozco, M.; Luque, J. *J. Org. Chem.* **2000**, *65*, 3074–3084; (c) Johnson, T. A.; Curtis, M. D.; Berk, P. *J. Am. Chem. Soc.* **2001**, *123*, 1004–1005; (d) Greenhalgh, D. A.; Simpkins, N. S. *Synlett* **2002**, 2074–2076; (e) Yamada, S.; Jahan, I. *Tetrahedron Lett.* **2005**, *46*, 8673–8676, and references cited therein.
18. Evans, D. A.; Fu, G. C.; Hoveyda, A. H. *J. Am. Chem. Soc.* **1992**, *114*, 6671–6679.
19. Enantiomeric excess was determined by HPLC analysis after protection of the secondary amine with a Boc group. See [Supplementary data](#) for detail.